Wu, Qiu Jing
Sun, Xiujun
Teves, Lucy
Mayor, Diana http://orcid.org/0000-0001-7598-1358
Tymianski, Michael http://orcid.org/0000-0002-6311-9565
Funding for this research was provided by:
Canada Research Chairs
Article History
Received: 25 November 2020
Accepted: 30 July 2021
First Online: 5 August 2021
Declarations
:
: Dr. Michael Tymianski (M.T.) is a Canada Research Chair (Tier 1) in Translational Stroke Research, and the CEO of NoNO Inc., a biotechnology company developing nerinetide (also termed NA-1 or Tat-NR2B9c) for clinical use. Q.J.W., X.J.S., L.T. and D.M. have no competing interests.
: All procedures performed involving animals were approved by the University Health Network animal care committee, conformed to Canadian Council of Animal Care guidelines, and ARRIVE guidelines (Kilkenny et al. CitationRef removed).